Today: 29 April 2026
Browse Category

CSE:NOVO-B 11 December 2025 - 6 February 2026

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk shares rose nearly 5% Friday after the FDA said it would target mass-marketed, unapproved drug copies. The move follows Hims & Hers launching a $49 compounded version of Novo’s Wegovy pill, prompting Novo to threaten legal action. The stock remains near its 52-week low after a sharp drop earlier this week. Investors await FDA enforcement and Novo’s next legal steps.
6 February 2026
··
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk’s Copenhagen shares are down nearly 50% in 2025, heading for their worst year on record. U.S. ADRs trade near $49 after a recent rebound. SEB now forecasts organic sales will fall in 2026, citing U.S. price cuts and pressure on Ozempic. Seeking Alpha downgraded the stock, pointing to structural challenges and slowing revenue growth.
11 December 2025
··

Stock Market Today

  • Omnicell Shares Surge Nearly 21% on Strong Q1 Earnings Beat
    April 28, 2026, 10:39 PM EDT. Omnicell (OMCL) surged nearly 21% on Tuesday after posting first-quarter revenue of just under $310 million, beating analyst estimates of $304 million. The healthcare tech company's product revenue rose 20%, while service revenue gained 8% year-over-year. Net income on a non-GAAP basis more than doubled to $25 million or $0.55 per share, surpassing expected $0.33 per share. Omnicell cited strong demand for its connected device portfolio and core healthcare solutions as drivers. The company raised its outlook for 2026 revenue to between $1.22 billion and $1.26 billion and lifted adjusted earnings per share guidance to $1.80-$2.00. Investors rewarded the solid execution, pushing shares to a new annual high amid optimism over growth in hospitals and pharmacies.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop